[1] |
Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T⁃cell stimulation[J]. Br J Clin Pharmacol, 2011, 71(5): 701⁃707. DOI: 10.1111/j.1365⁃2125.2010.03764.x.
|
[2] |
Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(h)⁃17, T(h)1 and T(h)2 cells[J]. Nat Immunol, 2009, 10(8): 864⁃871. DOI: 10.1038/ni.1770.
|
[3] |
Fujita H. The role of IL⁃22 and Th22 cells in human skin diseases[J]. J Dermatol Sci, 2013, 72(1): 3⁃8. DOI: 10.1016/j.jdermsci. 2013.04.028.
|
[4] |
刘锡钧. 实用药物指南[M]. 北京: 人民军医出版社, 2000: 771⁃772.
|
|
Liu XJ. Practical drug guide[M]. Beijing: people′s military medical press, 2000: 771⁃772.
|
[5] |
张学军. 皮肤性病学[M]. 8 版. 北京: 人民卫生出版社, 2008: 120⁃126.
|
|
Zhang XJ. Dermatovenereology[M]. Bei Jing: People′s medical publishing house, 2008: 120⁃126.
|
[6] |
Fujita H, Nograles KE, Kikuchi T, et al. Human Langerhans cells induce distinct IL⁃22⁃producing CD4+ T cells lacking IL⁃17 production[J]. Proc Natl Acad Sci U S A, 2009, 106(51): 21795⁃21800. DOI: 10.1073/pnas.0911472106.
|
[7] |
Wolk K, Witte E, Witte K, et al. Biology of interleukin⁃22[J]. Semin Immunopathol, 2010, 32(1): 17⁃31. DOI: 10.1007/s00281⁃009⁃0188⁃x.
|
[8] |
金旗, 熊丽霞. IL⁃13 Rα2作为功能受体介导信号转导的研究进展[J]. 中国病理生理杂志, 2014, 30(8): 1513⁃1518. DOI: 10.3969/j.issn.1000⁃4718.2014.08.031.
|
|
Jin Q, Xiong LX. IL⁃13Rα2 as a functional receptor mediates signal transduction[J]. Chin J Pathophysiol, 2014, 30(8): 1513⁃1518. DOI: 10.3969/j.issn.1000⁃4718.2014. 08.031.
|
[9] |
Eyerich K, Eyerich S. Th22 cells in allergic disease[J]. Allergo J Int, 2015, 24(1): 1⁃7. DOI: 10.1007/s40629⁃015⁃0039⁃3.
|
[10] |
Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin⁃homing memory T cells[J]. Nat Immunol, 2009, 10(8): 857⁃863. DOI: 10.1038/ni.1767.
|
[11] |
Pan HF, Li XP, Zheng SG, et al. Emerging role of interleukin⁃22 in autoimmune diseases[J]. Cytokine Growth Factor Rev, 2013, 24(1): 51⁃57. DOI: 10.1016/j.cytogfr.2012.07.002.
|
[12] |
吴少宾, 林岑珊, 蔡壬辛, 等. 药疹患者血清CCL17、 CCL27、 TNF⁃α和IL⁃10的测定[J]. 中山大学学报(医学科学版), 2015, 36(2): 241⁃244, 256.
|
|
Wu SB, Lin CS, Cai RX, et al. Serum levels and functions of CCL⁃17, CCL⁃27, TNF⁃α and IL⁃10 in patients with drug hypersensi⁃tivity reaction[J]. J Sun Yat⁃Sen Uni (Medical Sciences), 2015, 36(2): 241⁃244, 256.
|
[13] |
Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens⁃Johnson syndrome/toxic epidermal necrolysis[J]. Br J Dermatol, 2006, 155(4): 722⁃728. DOI: 10.1111/j.1365⁃2133.2006.07398.x.
|
[14] |
Eyerich S, Wagener J, Wenzel V, et al. IL⁃22 and TNF⁃α represent a key cytokine combination for epidermal integrity during infection with Candida albicans[J]. Eur J Immunol, 2011, 41(7): 1894⁃1901. DOI: 10.1002/eji.201041197.
|
[15] |
Hasegawa M, Yada S, Liu MZ, et al. Interleukin⁃22 regulates the complement system to promote resistance against pathobionts after pathogen⁃induced intestinal damage[J]. Immunity, 2014, 41(4): 620⁃632. DOI: 10.1016/j.immuni.2014.09.010.
|
[16] |
Yamamoto H, Kemper C. Complement and IL⁃22: partnering up for border patrol[J]. Immunity, 2014, 41(4): 511⁃513. DOI: 10.1016/j.immuni.2014.10.002.
|
[17] |
Carroll MV, Sim RB. Complement in health and disease[J]. Adv Drug Deliv Rev, 2011, 63(12): 965⁃975. DOI: 10.1016/j.addr.2011.06.005.
|
[18] |
Trouw LA, Daha MR. Role of complement in innate immunity and host defense[J]. Immunol Lett, 2011, 138(1): 35⁃37. DOI: 10.1016/ j.imlet.2011.02.014.
|
[19] |
Sun S, Guo Y, Zhao G, et al. Complement and the alternative pathway play an important role in LPS/D⁃GalN⁃induced fulminant hepatic failure[J/OL]. PLoS One, 2011, 6(11): e26838. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206060/. DOI: 10.1371/journal.pone.0026838.
|
[20] |
Pickering M, Cook HT. Complement and glomerular disease: new insights[J]. Curr Opin Nephrol Hypertens, 2011, 20(3): 271⁃277. DOI: 10.1097/MNH.0b013e328345848b.
|
[21] |
Navi D, Michael DJ, Fazel N. Drug⁃induced linear IgA bullous dermatosis[J]. Dermatol Online J, 2006, 12(5): 12.
|